Table 3.

Comparison of patients with no demonstrable inhibitor with those who had strong inhibitors

Outcome	No inhibitor (<1 BU/mL) (n = 27)				>2 BU/mL (n = 30)				P
	No.	%	Median	Range	No.	%	Median	Range
Platelets × 103/µL*			9	4-101			11	5-63	.12
Hematocrit, %*			20	14-33			22	13-28	.69
Creatinine, mg/dL			1.3	0.7-6.8			1.35	0.8-5.5	.86
LDH, U/L			1207	432-2962			1500	274-3909	.36
Severe neurologic abnormalities	12	44			18	60			.29
PEX			12	2-71			11	1-79	.79
Exacerbation	9	33			16/29*	55			.12
Survival	25	93			23	77			.15
Relapse	8/25	32			10/23	44			.55

Functional inhibitor activity was measured by the FRET assay. The 20 patients with an intermediate-strength inhibitor titer (1-2 BU/mL) were not included in this analysis.

^*One patient failed to respond and therefore could not be evaluated for exacerbation.